Moffitt Cancer Center researchers study use of dasatinib for patients with high-risk MDS

Researchers at Moffitt Cancer Center have completed a phase II clinical trial to determine the safety and efficacy of dasatinib for patients with higher-risk myelodysplastic syndromes , chronic myelomonocytic leukemia, or acute myeloid leukemia resulting from MDS and have failed treatment with azanucleosides.

http://www.eurekalert.org/pub_releases/2013-03/hlmc-mcc032013.php